Interleukin-6 promotes anti-OspA borreliacidal antibody production in vitro

Clinical and Vaccine Immunology

Volumn 13, Issue 1, 2006, Pages 19-25

  Munson, Erik L ^a,b,d   Nardelli, Dean T ^a,b   Luk, K H Kevin ^a,b   Remington, Monica C ^a,b   Callister, Steven M ^c   Schell, Ronald F ^a,b  

^a WISCONSIN STATE LABORATORY OF HYGIENE   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^d Medical Science Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; BACTERIUM ANTIBODY; BORRELIA VACCINE; GAMMA INTERFERON ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; OUTER SURFACE PROTEIN A; RECOMBINANT INTERLEUKIN 6; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL CELL; ANIMAL TISSUE; ANTIBODY PRODUCING CELL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; BACTERICIDAL ACTIVITY; BORRELIA BURGDORFERI; IN VITRO STUDY; LYMPH NODE CELL; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINE PRODUCTION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, SURFACE; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; BORRELIA BURGDORFERI; CELLS, CULTURED; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-6; LIPOPROTEINS; LYMPH NODES; MICE; MICE, INBRED C3H; RECOMBINANT PROTEINS;

EID: 33645129720     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.13.1.19-25.2006     Document Type: Article

References (38)

1. Anguita, J., M. Rincon, S. Samanta, S. W. Barthold, R. A. Flavell, and E. Fikrig. 1998. Borrelia burgdorferi-infected, interleukin-6-deficient mice have decreased Th2 responses and increased Lyme arthritis. J. Infect. Dis. 178: 1512-1515.
2. Aydintug, M. K., Y. Gu, and M. T. Philipp. 1994. Borrelia burgdorferi antigens that are targets of antibody-dependent, complement-mediated killing in the rhesus monkey. Infect. Immun. 62:4929-4937.
3. Barbour, A. G. 1984. Isolation and cultivation of Lyme disease spirochetes. Yale J. Biol. Med. 57:521-525.
4. Callister, S. M., K. L. Case, W. A. Agger, R. F. Schell, R. C. Johnson, and J. L. E. Ellingson. 1990. Effects of bovine serum albumin on the ability of Barbour-Stoenner-Kelly medium to detect Borrelia burgdorferi. J. Clin. Microbiol. 28:363-365.
5. Callister, S. M., D. A. Jobe, R. F. Schell, C. S. Pavia, and S. D. Lovrich. 1996. Sensitivity and specificity of the borreliacidal antibody test during early Lyme disease: a "gold standard"? Clin. Diagn. Lab. Immunol. 3:399-402.
6. Callister, S. M., and R. F. Schell. 1994. Importance of protective borreliacidal antibodies in Lyme disease immunity and serodiagnosis. J. Infect. Dis. 170:499-500.
7. Callister, S. M., R. F. Schell, K. L. Case, S. D. Lovrich, and S. P. Day. 1993. Characterization of the borreliacidal antibody response to Borrelia burgdorferi in humans: a serodiagnostic test. J. Infect. Dis. 167:158-164.
8. Callister, S. M., R. F. Schell, and S. D. Lovrich. 1991. Lyme disease assay which detects killed Borrelia burgdorferi. J. Clin. Microbiol. 29:1773-1776.
9. Durum, S. K., and J. J. Oppenheim. 1989. Macrophage-derived mediators: interleukin 1, tumor necrosis factor, interleukin 6, interferon, and related cytokines, p. 639-661. In W. E. Paul (ed.), Fundamental immunology, 2nd ed. Raven Press, Ltd., New York, N.Y.
10. Fikrig, E., S. W. Barthold, F. S. Kantor, and R. A. Flavell. 1990. Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science 250:553-556.
11. Fikrig, E., S. W. Barthold, F. S. Kantor, and R. A. Flavell. 1992. Long-term protection of mice from Lyme disease by vaccination with OspA. Infect. Immun. 60:773-777.
12. Fikrig, E., S. W. Barthold, N. Marcantoni, K. Deponte, F. S. Kantor, and R. A. Flavell. 1992. Role of OspA, OspB, and flagellin in protective immunity of Lyme borreliosis in the laboratory mouse. Infect. Immun. 60:657-661.
13. Johnson, B. J. B., S. L. Sviat, C. M. Happ, J. J. Dunn, J. C. Frantz, L. W. Mayer, and J. Piesman. 1995. Incomplete protection of hamsters vaccinated with unlipidated OspA from Borrelia burgdorferi infection is associated with low levels of antibody to an epitope defined by mAb LA-2. Vaccine 13:1086-1094.
14. Laemmli, U. K. 1970. Cleavage of the structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 227:680-685.
15. Lovrich, S. D., S. M. Callister, B. K. Du Chateau, L. C. Lim, J. Winfrey, S. P. Day, and R. F. Schell. 1995. Abilities of OspA proteins from different seroprotective groups of Borrelia burgdorferi to protect hamsters from infection. Infect. Immun. 63:2113-2119.
16. Ma, J., P. M. Gingrich-Baker, P. M. Franchi, P. Bulger, and R. T. Coughlin. 1995. Molecular analysis of neutralizing epitopes on outer surface proteins A and B of Borrelia burgdorferi. Infect. Immun. 63:2221-2227.
17. Ma, Y., and J. J. Weis. 1993. Borrelia burgdorferi outer surface lipoproteins OspA and OspB possess B-cell mitogenic and cytokine-stimulatory properties. Infect. Immun. 61:3843-3853.
18. Moskophidis, M., and B. Luther. 1993. Monoclonal antibodies with in vitro borreliacidal activities define the outer surface proteins A and B of Borrelia burgdorferi. Zentbl. Bakteriol. 279:201-213.
19. Munson, E. L., B. K. Du Chateau, J. R. Jensen, S. M. Callister, D. J. DeCoster, and R. F. Schell. 2002. Gamma interferon inhibits production of anti-OspA borreliacidal antibody in vitro. Clin. Diagn. Lab. Immunol. 9:1095-1101.
20. Munson, E. L., B. K. Du Chateau, D. A. Jobe, S. D. Lovrich, S. M. Callister, and R. F. Schell. 2000. Production of borreliacidal antibody to outer surface protein A in vitro and modulation by interleukin-4. Infect. Immun. 68:5496-5501.
21. Munson, E. L., D. J. DeCoster, D. T. Nardelli, D. M. England, S. M. Callister, and R. F. Schell. 2004. Neutralization of gamma interferon augments borreliacidal antibody production and severe destructive Lyme arthritis in C3H/HeJ mice. Clin. Diagn. Lab. Immunol. 11:35-41.
22. 6, the conserved immunodominant region of VIsE surface protein of Borrelia burgdorferi. 2004. Clin. Diagn. Lab. Immunol. 11:458-462.
23. Padilla, M. L., S. M. Callister, R. F. Schell, G. L. Bryant, D. A. Jobe, S. D. Lovrich, B. K. Du Chateau, and J. R. Jensen. 1996. Characterization of the protective borreliacidal antibody response in humans and hamsters after vaccination with a Borrelia burgdorferi outer surface protein A vaccine. J. Infect. Dis. 174:739-746.
24. Paludan, S. R. 1998. Interleukin-4 and interferon-γ: the quintessence of a mutual antagonistic relationship. Scand. J. Immunol. 48:459-468.
25. Paul, W. E., and J. Ohara. 1987. B-cell stimulating factor-1/interleukin 4. Annu. Rev. Immunol. 5:429-459.
26. Probert, W. S., and R. B. LeFebvre. 1994. Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen. Infect. Immun. 62:1920-1926.
27. Remington, M. C., E. L. Munson, S. M. Callister, M. L. Molitor, J. A. Christopherson, D. J. DeCoster, S. M. Lovrich, and R. F. Schell. 2001. Interleukin-6 enhances production of anti-OspC immunoglobulin G2b borreliacidal antibody. Infect. Immun. 69:4268-4275.
28. Rincon, M., J. Anguita, T. Nakamura, E. Fikrig, and R. A. Flavell. 1997. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4 T cells. J. Exp. Med. 185:461-469.
29. Sambri, V., S. Armati, and R. Cevinini. 1993. Animal and human antibodies reactive with the outer surface protein A and B of Borrelia burgdorferi are borreliacidal, in vitro, in presence of complement. FEMS Immunol. Med. Microbiol. 7:67-72.
30. Schaible, U. E., M. D. Kramer, K. Eichmann, M. Modolell, C. Museteanu, and M. M. Simon. 1990. Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice. Proc. Natl. Acad. Sci. USA 87:3768-3772.
31. Schoenfeld, R., B. Araneo, Y. Ma, L. M. Yang, and J. J. Weis. 1992. Demonstration of a B-lymphocyte mitogen produced by the Lyme disease pathogen, Borrelia burgdorferi. Infect. Immun. 60:455-464.
32. Sigal, L. H., J. M. Zahradnik, P. Lavin, S. J. Patella, G. Bryant, R. Haselby, E. Hilton, M. Kunkel, D. Adler-Klein, T. Doherty, J. Evans, and S. Malawista. 1998. A vaccine consisting of recombinant Borrelia burgdorferi outer surface protein A to prevent Lyme disease. N. Engl. J. Med. 339:216-222.
33. Simon, M. M., U. E. Schaible, M. D. Kramer, C. Eckershorn, C. Museteanu, H. K. Muller-Hermelink, and R. Wallich. 1991. Recombinant outer surface protein A from Borrelia burgdorferi induces antibodies protective against spirochaetal infection in mice. J. Infect. Dis. 164:123-132.
34. Steere, A. C., V. K. Sikand, F. Meurice, D. L. Parenti, E. Fikrig, R. T. Schoen, J. Nowakowski, C. H. Schmid, S. Laukamp, C. Buscarino, and D. S. Krause. 1998. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme disease vaccine study group. N. Engl. J. Med. 339:209-215.
35. Straubinger, R. K., Y. Chang, R. H. Jacobson, and M. J. G. Appel. 1995. Sera from OspA-vaccinated dogs, but not from tick-infected dogs, inhibit in vitro growth of Borrelia burgdorferi. J. Clin. Microbiol. 33:2745-2751.
36. Triola, M. F. 1992. Elementary statistics, 5th ed. Addison-Wesley, Boston, Mass.
37. Van Hoecke, C., E. Lebacq, J. Beran, and D. Parenti. 1999. Alternative vaccination schedules (0, 1, and 6 months versus 0, 1, and 12 months) for a recombinant OspA Lyme disease vaccine. Clin. Infect. Dis. 28:1260-1264.
38. Yang, L., Y. Ma, R. Schoenfeld, M. Griffiths, E. Eichwald, B. Araneo, and J. J. Weis. 1992. Evidence for B-lymphocyte mitogen activity in Borrelia burgdorferi-mtecled mice. Infect. Immun. 60:3033-3041.